Pfizer (NYSE:PFE) reported positive Phase 3 results for LITFULO in nonsegmental vitiligo. The company plans to pursue global ...
Berobenatide is one of the keys to Pfizer's future.
Pfizer Q2 2026 earnings beat Wall Street estimates as non-COVID revenue surged 18% operationally, Eliquis topped $2.43B, and ...
Pfizer Inc. PFE stock rose Tuesday after the drugmaker reported better-than-expected second-quarter results and raised its ...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced top-line ABRYSVO ® vaccine efficacy and safety data for respiratory syncytial virus (RSV) in adults 60 years of age and older ...
Pfizer (PFE) on Saturday reported detailed results from several mid-stage trials, noting that its obesity therapy, berobenatide (PF’3944), added from its Metsera acquisition last year, could become ...
NEW YORK & MAINZ, GERMANY--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive topline results from a Phase 1/2 study (NCT05596734) evaluating the safety, ...
Pfizer has rolled out detailed trial data suggesting Tukysa could be part of a new first-line treatment to delay the progression of HER2-positive breast cancer. The current standard of care for the ...
Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo has shown efficacy in immunocompromised adults, the pharma announced Monday. In substudy B of Pfizer’s ongoing Phase 3 MONeT trial, Abrysvo ...
Pfizer wants a chunk of the budding weight loss drug market, which it believes could eventually grow to $90 billion. But analysts said that upcoming data on Pfizer's experimental obesity pill, ...
Pfizer highlighted the performance of a weight-loss drug it acquired in last year's deal to buy Metsera. Pfizer's stock closed 3% lower on Tuesday after investors were disappointed by limited midstage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results